University of California, San Francisco and Phase Holographic Imaging establish Center of Excellence

University of California, San Francisco (UCSF) and Phase Holographic Imaging (PHI) have agreed to expand their on-going collaboration and establish a regional Holographic Imaging Cytometry Center of Excellence, located at the UCSF Helen Diller Family Comprehensive Cancer Center.

By providing education and technical support, the center will bring the benefits of holographic imaging to the UCSF research community. The recurring UCSF-PHI symposium will continue to serve as a forum for scientists worldwide who develop new therapies and diagnostic techniques for melanoma and other cancers.

The realization that a very small sub-population of rare cancer cells controls tumor growth and spreading has led to a growing demand for a new generation of scientific instruments that can individually analyze unstained cancer cells over several cell generations, while maintaining physiological relevance.

“Our research focuses on identifying the needle in the haystack — finding, within the myriad of cell types that constitute human skin, the very rare cells with the highest potential for transforming into aggressive cancers. Experimentally, this translates to monitoring the behavior and morphology of individual cells in a large population. Holographic imaging cytometry is a label-free and quantitative method that allows us to conduct these experiments. Our collaboration with PHI has been instru­mental in establishing this emerging technology at UCSF. My team has worked closely with PHI scientists for over three years to develop the strategies needed for our research, permitting us to ask questions previously closed to us. With the establish­ment of the Center of Excellence we continue this productive partnership to advance both the breadth of applications for holographic cytometry and the diversity of research laboratories at UCSF, utilizing these approaches”, said Dr. Robert Judson-Torres, Principal Investigator at UCSF.

Peter Egelberg, CEO of PHI, explains: “As human cells are transparent, conventional cell analysis methods generally require that the cells are either invasively stained biochemically or through genetic mani­pulation. Fluorescent and other stains are visible because they partially absorb the illumi­nating light. The absorbed light is transformed into energy that harms the cells, which compromises physiological relevance and limits the ability to analyze cells over time. Holographic imaging cytometry instead visualizes the cells individually without stains, by quantifying how the illuminating light is distorted when passing through the transparent cells.”

The speakers at the UCSF-PHI symposium 2018

“In presentations at SPIE 2018 and at this year’s UCSF-PHI symposium, Dr. Judson-Torres showed that by combining holographic imaging cytometry with machine-learning his team was able to non-invasively characterize and classify individual cancer cells, with an accuracy of 95 %. We look forward to continue supporting UCSF researchers when they build on these encouraging results to further define the future role of holographic imaging cytometry and machine-learning in cancer research”, Egelberg concludes.

REFERENCES

UC Disclaimer: The Information stated above was prepared by PHI and reflects solely the opinion of PHI. Nothing in this statement should be construed to imply any support or endorsement of PHI, or any of its products, by the Regents of the University of California, its officers, agents and employees.

ABOUT UCSF

University of California, San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, transitional and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises three top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area. Please visit www.ucsf.edu/news.

ABOUT PHI

PHI leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Head-quartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collabora­tions in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

For additional information, please contact:
Peter Egelberg, CEO

Tel: +46 703 19 42 74
E-mail: ir@phiab.se
Web: www.phiab.se

This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on February 26, 2018.

About Us

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first HoloMonitor instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Head-quartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

Subscribe

Media

Media